Bruker Corporation (NASDAQ:BRKR) had its price objective trimmed by Jefferies Group LLC from $30.00 to $28.00 in a research note issued to investors on Monday morning. The firm currently has a buy rating on the stock.
Several other research analysts have also commented on BRKR. Zacks Investment Research upgraded shares of Bruker Corporation from a hold rating to a buy rating and set a $24.00 price target on the stock in a research note on Thursday, December 15th. Cantor Fitzgerald set a $28.00 price target on shares of Bruker Corporation and gave the stock a buy rating in a research note on Wednesday, December 7th. Deutsche Bank AG restated a hold rating and set a $24.00 price target on shares of Bruker Corporation in a research note on Wednesday, January 18th. J P Morgan Chase & Co lowered shares of Bruker Corporation from an overweight rating to a neutral rating and dropped their price target for the stock from $23.00 to $20.00 in a research note on Wednesday, December 14th. Finally, Barclays PLC lowered shares of Bruker Corporation from an overweight rating to an equal weight rating and dropped their price target for the stock from $30.00 to $22.00 in a research note on Wednesday, January 4th. Two research analysts have rated the stock with a sell rating, twelve have given a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. The company has an average rating of Hold and an average price target of $24.78.
Shares of Bruker Corporation (NASDAQ:BRKR) opened at 23.06 on Monday. The stock has a 50 day moving average of $21.99 and a 200-day moving average of $22.37. The firm has a market cap of $3.69 billion, a price-to-earnings ratio of 26.06 and a beta of 1.02. Bruker Corporation has a 52 week low of $19.58 and a 52 week high of $29.85.
Bruker Corporation (NASDAQ:BRKR) last announced its quarterly earnings results on Wednesday, November 2nd. The company reported $0.32 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.20 by $0.12. Bruker Corporation had a net margin of 9.02% and a return on equity of 26.05%. The company had revenue of $393.90 million for the quarter, compared to analyst estimates of $394.14 million. During the same quarter in the prior year, the business posted $0.19 EPS. Bruker Corporation’s quarterly revenue was down .6% on a year-over-year basis. Equities research analysts expect that Bruker Corporation will post $1.10 earnings per share for the current year.
In other Bruker Corporation news, Director Ingen Chris Van sold 20,000 shares of the firm’s stock in a transaction on Tuesday, December 13th. The shares were sold at an average price of $22.29, for a total value of $445,800.00. Following the sale, the director now directly owns 5,000 shares in the company, valued at approximately $111,450. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Frank H. Laukien purchased 2,124 shares of the firm’s stock in a transaction on Friday, November 25th. The stock was bought at an average price of $22.90 per share, for a total transaction of $48,639.60. Following the completion of the transaction, the chief executive officer now directly owns 37,699,606 shares in the company, valued at $863,320,977.40. The disclosure for this purchase can be found here. Company insiders own 35.80% of the company’s stock.
A number of hedge funds have recently bought and sold shares of BRKR. Price T Rowe Associates Inc. MD raised its stake in Bruker Corporation by 2.3% in the third quarter. Price T Rowe Associates Inc. MD now owns 28,980,167 shares of the company’s stock valued at $656,401,000 after buying an additional 661,337 shares in the last quarter. Vanguard Group Inc. raised its stake in Bruker Corporation by 5.3% in the second quarter. Vanguard Group Inc. now owns 9,442,355 shares of the company’s stock valued at $214,719,000 after buying an additional 476,468 shares in the last quarter. AQR Capital Management LLC raised its stake in Bruker Corporation by 89.9% in the second quarter. AQR Capital Management LLC now owns 2,397,638 shares of the company’s stock valued at $54,522,000 after buying an additional 1,135,146 shares in the last quarter. Boston Partners raised its stake in Bruker Corporation by 69.2% in the third quarter. Boston Partners now owns 2,177,771 shares of the company’s stock valued at $49,327,000 after buying an additional 890,436 shares in the last quarter. Finally, Emerald Acquisition Ltd. raised its stake in Bruker Corporation by 11.5% in the third quarter. Emerald Acquisition Ltd. now owns 1,663,154 shares of the company’s stock valued at $37,670,000 after buying an additional 171,696 shares in the last quarter. Institutional investors own 67.69% of the company’s stock.
About Bruker Corporation
Bruker Corporation is a designer and manufacturer of scientific instruments, and analytical and diagnostic solutions. The Company’s operating segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.